We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Study: Pharma should invest in public health campaigns

Study: Pharma should invest in public health campaigns

April 19, 2011
CenterWatch Staff

Pharmaceutical companies should consider investing in public health campaigns as a way to help with the challenges facing healthcare systems, according to a report discussed in Pharma Times.

The study was conducted by the Economist Intelligence Unit and commissioned by Digitas Health Europe.  It questioned 450 healthcare professionals in Europe, Latin America, China and India and discovered that 32.4% believed investing in public health campaigns was an important factor for pharmaceutical companies.

Nearly 100% of the respondents stated that awareness campaigns that focus on preventative medicine and encourage people to take control of their own health were a valuable part of the industry.

About 70% of healthcare professionals felt chronic metabolic diseases, such as diabetes, as their country’s primary challenge; ageing populations was next at 34.4%; infectious diseases can in at 25.8% and drug and alcohol abuse at 23%.

Overall, the biggest challenge to the countries’ healthcare systems was lack of funding, health care providers reported.

Iain Scott, managing editor at the Economist Intelligence Unit, said the research revealed what the industry was facing: “There’s also a clear indication of where pharma companies ought to place themselves. Doctors value the information they receive from drug firms and they see a big role for pharma in helping take some pressure off healthcare systems by supporting public health campaigns.”

Upcoming Events

  • 09Dec

    The Age of eSource: Modernizing Clinical Trials

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Patient-phsyician-consultation

    Giving Patients Back Their Voice in Clinical Trials

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing